Status:
COMPLETED
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
Lead Sponsor:
EMD Serono Research & Development Institute, Inc.
Collaborating Sponsors:
Merck KGaA, Darmstadt, Germany
Conditions:
Relapsing-Remitting Multiple Sclerosis
Eligibility:
All Genders
50+ years
Brief Summary
This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade o...
Eligibility Criteria
Inclusion
- RRMS subjects who have been treated with interferon beta 1a SC 44 micro-gram thrice a week and dimethyl fumarate in inpatient or outpatient settings during the period from January 1, 2015 to December 31, 2015.
- Subjects with at least one year of laboratory values post-index date to analyze lymphocyte counts, and CD4 and CD8 counts. The date of first blood draw for laboratory tests after January 1, 2015 will be defined as the subject's index date.
Exclusion
- \- Subjects who have been on treatment for less than 1 year after their index date.
Key Trial Info
Start Date :
August 23 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 11 2018
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT03284970
Start Date
August 23 2017
End Date
May 11 2018
Last Update
August 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurology Center of New England
Foxborough, Massachusetts, United States, 02035